NewsSource: EClinCloud

Worried about being replaced by ChatGPT? Join EClinCloud and be irreplaceable!

1 min readEClinCloud Editorial Team
News header image for "Worried about being replaced by ChatGPT? Join EClinCloud and be irreplaceable!"

Source: EClinCloud.

Article illustration



About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interoperable, all-in-one cloud platform for clinical trials (including technology products such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent, as well as solutions including scale management, linguistic validation, rater training, and data quality analysis) and clinical trial endpoint assessment technologies across therapeutic areas (such as oncology, central nervous system, and ophthalmology). Combining cutting-edge technology with life data, EClinCloud is building a globally leading, patient-centric SaaS cloud platform for clinical evidence support to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and devices, and benefit countless patients.




Article illustration

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.